Investigational drug · Phase 2
NH102
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Major Depressive Disorder (MDD).
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "NH102"
First trial start
2024
Dec 4, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NH102", any sponsor or status.
Conditions studied
As listed on its trial records.
- Major Depressive Disorder (MDD)
Approved drugs for the same conditions: Depression (major depressive disorder) · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "NH102" as an intervention, largest first.
- A Phase II Study to Evaluate NH102 for DepressionPivotal-lookingCompleted
Jiangsu Nhwa Pharmaceutical Co., Ltd.Industry
NCT06842992 · 243 participants · Start Dec 4, 2024 · Primary completion Jul 30, 2025
Drug: NH102; NH102 and 3 more · For: Major Depressive Disorder (MDD)
Sites: Hefei, China; Beijing, China; Chongqing, China · 24 sites in all
Jiangsu Nhwa Pharmaceutical Co., Ltd.Industry
NCT05015192 · 55 participants · Start Aug 12, 2021 · Primary completion Jan 11, 2022
Drug: NH102; Placebo · For: Depression
Sites: Shanghai, China
Jiangsu Nhwa Pharmaceutical Co., Ltd.Industry
NCT07324408 · 40 participants · Start Mar 10, 2022 · Primary completion Apr 10, 2023
Drug: NH102; Placebo · For: Depression
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- [Inhibitory effects of LHRH on LH receptors in the rat testis].
Auclair C, Ferland L, Cusan L, et al. · C R Acad Hebd Seances Acad Sci D 1978
Also in development for Major Depressive Disorder (MDD)
- KH607Phase 34 trials
Chengdu Kanghong Pharmaceutical Group Co., Ltd. · Major Depressive Disorder (MDD), Postpartum Depressive Disorder
- CYB003Phase 33 trials
Cybin IRL Limited · Major Depressive Disorder, Major Depressive Disorder (MDD), Depression in Adults
- Bupropion Sustained-ReleasePhase 31 trial
CSPC Ouyi Pharmaceutical Co., Ltd. · Major Depressive Disorder (MDD)
- DT-101Phase 22 trials
Draig Therapeutics Ltd · Major Depressive Disorder (MDD)
- SPT-300LYT-300, GlyphAlloPhase 22 trials
Seaport Therapeutics · Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
- ACP-211Phase 21 trial
ACADIA Pharmaceuticals Inc. · Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant
- SPN-821Phase 21 trial
Supernus Pharmaceuticals, Inc. · Major Depressive Disorder (MDD)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.